Correction of metabolic acidosis after conversion from sevelamer hydrochloride to lanthanum carbonate
نویسندگان
چکیده
Correction of metabolic acidosis after conversion from sevelamer hydrochloride to lanthanum carbonate Sir, We recently introduced lanthanum carbonate as an alternative phosphate binder to sevelamer hydrochloride in patients with elevated serum calcium. Lanthanum carbonate has a higher affinity for phosphate than sevelamer HCl, so fewer lanthanum carbonate tablets are required to achieve the same phosphate control. To reduce the pill burden in patients on high doses of sevelamer HCl, a policy of converting patients who were prescribed 8–12 sevelamer per day, and patients currently on 6 sevelamer per day but in need of a dose increase, to 3 × 750 mg lanthanum car-bonate per day was established. Conversions were made at the discretion of the doctor, so that well-controlled patients were less likely to switch. In October 2007, 60 haemodialysis patients converted according to the above criteria. Of these, 13 patients who disliked or were intolerant of lanthanum carbonate reverted to sevelamer HCl within 3 months. Forty-seven patients (68% male, median age 47 years, range 21–79) continued to take lanthanum carbonate. Several studies have suggested that sevelamer HCl contributes to metabolic acidosis [1,2], while lanthanum car-bonate would be expected to have an antacid effect. A comparison of the median of three routine (monthly) pre-dialysis serum bicarbonate and phosphate measurements immediately before and after conversion for each patient showed an increase in serum bicarbonate from a mean of 20.3 ± 2.3 to 22.2 ± 2.4 mmol/l (P < 0.0001, paired t-test), see Figure 1. There was no wash-out period for these patients, so it is not clear whether the change in bicarbonate was due to the discontinuation of sevelamer or the initiation of lanthanum carbonate. It is noteworthy that the increase in bicarbonate was significantly lower in the 15 patients that were prescribed 6 sevelamer per day prior to the conversion (0.7 ± 1.9 versus 2.3 ± 2.6 mmol/l, P = 0.04, unpaired t-test). This is in keeping with previous data suggesting that the degree of acidosis is related to the dose of sevelamer [2]. Phosphate levels were unchanged (mean before and after conversion 2.02 ± 0.53 and 1.97 ± 0.50 mmol/l, respectively). At the time of this analysis, the dose of lanthanum had not been titrated. Phosphate levels increased by an average of 0.25 mmol/l in the six patients who were on the maximum dose of sevelamer, suggesting that patients taking more than 9 sevelamer per day should convert to …
منابع مشابه
Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
Correction of metabolic acidosis after conversion from sevelamer hydrochloride to lanthanum carbonate Sir, We recently introduced lanthanum carbonate as an alternative phosphate binder to sevelamer hydrochloride in patients with elevated serum calcium. Lanthanum carbonate has a higher affinity for phosphate than sevelamer HCl, so fewer lanthanum carbonate tablets are required to achieve the sam...
متن کاملPA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure
The effects of PA21, a novel iron-based and non-calcium-based phosphate binder, on hyperphosphatemia and its accompanying bone abnormality in chronic kidney disease-mineral and bone disorder (CKD-MBD) were evaluated. Rats with adenine-induced chronic renal failure (CRF) were prepared by feeding them an adenine-containing diet for four weeks. They were also freely fed a diet that contained PA21 ...
متن کاملSevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
Sevelamer carbonate is an anion exchange pharmaceutical, developed to improve on the performance of the non-absorbable, non-calcium, and metal-free phosphate binder sevelamer hydrochloride. Sevelamer carbonate is expected not to worsen metabolic acidosis, as previously reported during long-term treatment with sevelamer hydrochloride in hemodialysis (HD) patients. Carbonate is the alternate coun...
متن کاملPharmacology of the Phosphate Binder, Lanthanum Carbonate
Studies were conducted to compare the phosphate-binding efficacy of lanthanum carbonate directly with other clinically used phosphate binders and to evaluate any potential adverse pharmacology. To examine the phosphate-binding efficacy, rats with normal renal function and chronic renal failure received lanthanum carbonate, aluminum hydroxide, calcium carbonate, or sevelamer hydrochloride in sev...
متن کاملLanthanum carbonate for dialysis patients with hyperphosphataemia resistant to sevelamer: A retrospective cohort study
Introduction: Lanthanum carbonate (LC) and sevelamer hydrochloride (SH) are non-calcium-based phosphate binders (NCPB), used to manage hyperphosphatemia in patients with chronic kidney disease. We compared the efficacy of LC and SH in lowering serum phosphate level in patients on haemodialysis or continuous ambulatory peritoneal dialysis. Methods: Treatment profiles of a group of dialysis patie...
متن کامل